source
- Altimmune’s pemvidutide cuts heavy drinking days in phase 2 AUD trialAltimmune announced that its experimental dual GLP-1/glucagon receptor agonist pemvidutide reduced heavy drinking in a phase‑2 study of alcohol use disorder. In the 24‑week Reclaim trial, particip…
- Pharma deals in China face heightened IP risk under U.S. BIOSECURE ActPharma companies are increasing licensing activity in China, but experts say patent attorneys must now factor in the geopolitical implications of the BIOSECURE Act. The legislation seeks to compil…